Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?

Douglas R. Stewart, Joy D. Cogan, Mordechai R. Kramer, Wallace T. Miller, Leif E. Christiansen, Michael W. Pauciulo, Ludwine M. Messiaen, George S. Tu, William H. Thompson, Reed E. Pyeritz, Jay H Ryu, William C. Nichols, Makoto Kodama, Barbara O. Meyrick, David J. Ross

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. Methods: We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which is mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Results: Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Conclusions: Our findings suggest that NF1 should be considered as being "associated with PAH"as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.

Original languageEnglish (US)
Pages (from-to)798-808
Number of pages11
JournalChest
Volume132
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Neurofibromatosis 1
Pulmonary Hypertension
Lung
Autopsy
Plexiform Neurofibroma
Bone and Bones
Mutation
Genetic Testing
Tumor Suppressor Genes
Genes
Proteins
Thorax

Keywords

  • Bone morphogenic protein 2
  • Mosaic perfusion pattern of lung attenuation
  • Neurofibromatosis type 1
  • Plexiform arteriopathy
  • Vasculopathy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Stewart, D. R., Cogan, J. D., Kramer, M. R., Miller, W. T., Christiansen, L. E., Pauciulo, M. W., ... Ross, D. J. (2007). Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy? Chest, 132(3), 798-808. https://doi.org/10.1378/chest.06-3017

Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy? / Stewart, Douglas R.; Cogan, Joy D.; Kramer, Mordechai R.; Miller, Wallace T.; Christiansen, Leif E.; Pauciulo, Michael W.; Messiaen, Ludwine M.; Tu, George S.; Thompson, William H.; Pyeritz, Reed E.; Ryu, Jay H; Nichols, William C.; Kodama, Makoto; Meyrick, Barbara O.; Ross, David J.

In: Chest, Vol. 132, No. 3, 09.2007, p. 798-808.

Research output: Contribution to journalArticle

Stewart, DR, Cogan, JD, Kramer, MR, Miller, WT, Christiansen, LE, Pauciulo, MW, Messiaen, LM, Tu, GS, Thompson, WH, Pyeritz, RE, Ryu, JH, Nichols, WC, Kodama, M, Meyrick, BO & Ross, DJ 2007, 'Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?', Chest, vol. 132, no. 3, pp. 798-808. https://doi.org/10.1378/chest.06-3017
Stewart DR, Cogan JD, Kramer MR, Miller WT, Christiansen LE, Pauciulo MW et al. Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy? Chest. 2007 Sep;132(3):798-808. https://doi.org/10.1378/chest.06-3017
Stewart, Douglas R. ; Cogan, Joy D. ; Kramer, Mordechai R. ; Miller, Wallace T. ; Christiansen, Leif E. ; Pauciulo, Michael W. ; Messiaen, Ludwine M. ; Tu, George S. ; Thompson, William H. ; Pyeritz, Reed E. ; Ryu, Jay H ; Nichols, William C. ; Kodama, Makoto ; Meyrick, Barbara O. ; Ross, David J. / Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?. In: Chest. 2007 ; Vol. 132, No. 3. pp. 798-808.
@article{c2d1763defc743faad317322f7f6806a,
title = "Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?",
abstract = "Background: Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. Methods: We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which is mutated in 70{\%} of patients with familial PAH and approximately 25{\%} of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Results: Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Conclusions: Our findings suggest that NF1 should be considered as being {"}associated with PAH{"}as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.",
keywords = "Bone morphogenic protein 2, Mosaic perfusion pattern of lung attenuation, Neurofibromatosis type 1, Plexiform arteriopathy, Vasculopathy",
author = "Stewart, {Douglas R.} and Cogan, {Joy D.} and Kramer, {Mordechai R.} and Miller, {Wallace T.} and Christiansen, {Leif E.} and Pauciulo, {Michael W.} and Messiaen, {Ludwine M.} and Tu, {George S.} and Thompson, {William H.} and Pyeritz, {Reed E.} and Ryu, {Jay H} and Nichols, {William C.} and Makoto Kodama and Meyrick, {Barbara O.} and Ross, {David J.}",
year = "2007",
month = "9",
doi = "10.1378/chest.06-3017",
language = "English (US)",
volume = "132",
pages = "798--808",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?

AU - Stewart, Douglas R.

AU - Cogan, Joy D.

AU - Kramer, Mordechai R.

AU - Miller, Wallace T.

AU - Christiansen, Leif E.

AU - Pauciulo, Michael W.

AU - Messiaen, Ludwine M.

AU - Tu, George S.

AU - Thompson, William H.

AU - Pyeritz, Reed E.

AU - Ryu, Jay H

AU - Nichols, William C.

AU - Kodama, Makoto

AU - Meyrick, Barbara O.

AU - Ross, David J.

PY - 2007/9

Y1 - 2007/9

N2 - Background: Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. Methods: We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which is mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Results: Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Conclusions: Our findings suggest that NF1 should be considered as being "associated with PAH"as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.

AB - Background: Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. Methods: We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which is mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Results: Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Conclusions: Our findings suggest that NF1 should be considered as being "associated with PAH"as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.

KW - Bone morphogenic protein 2

KW - Mosaic perfusion pattern of lung attenuation

KW - Neurofibromatosis type 1

KW - Plexiform arteriopathy

KW - Vasculopathy

UR - http://www.scopus.com/inward/record.url?scp=35448991256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448991256&partnerID=8YFLogxK

U2 - 10.1378/chest.06-3017

DO - 10.1378/chest.06-3017

M3 - Article

C2 - 17573495

AN - SCOPUS:35448991256

VL - 132

SP - 798

EP - 808

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -